Bishal Gyawali, Associate Professor at Queen’s University, Kingston, shared a post on X:
“Ever wondered why the results of 3 immunotherapy trials in urothelial cancers are different? Is it truly because the 3 drugs are different?
In this smart study led by Tomer Meirson, we show that these differences can all be explained by differential censoring alone! ”
Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring
Authors: Tomer Meirson, Jonathan Ofer, Noa Zimhony-Nissim, Avital Bareket-Samish, Gal Markel, Victoria Neiman, Nathan Cherny, Daniel A. Goldstein, Bishal Gyawali, Ian Tannock, Eli Rosenbaum.
